Clinical Trials

  • This study is looking to compare the regular dose flu shot to a high dose flu shot, in patients who have had a heart attack in the past year, or have been in the hospital for heart failure in the past 2 years. All subjects enrolled will receive a flu shot and will be closely monitored by the study team.
  • The purpose of this study is to deterimine if the Drug-Coated Chocolate Touch Balloon Catheters is safe and effective compared to a drug-coated balloon that is already approved in patients with a blockage in the blood vessels of their leg.
  • This study has been designed to treat patients with a pulmonary conduit or valve that has a large amount of regurgitation or is too narrow and needs to be replaced.
  • The study has been designed to demonstrate the efficacy and safety of the Paradise Renal Denervation System when treating patients with high blood pressure known as hypertension. When blood pressure is persistently elevated and pushes against the walls of the artery over a long period of time it is known to cause Hypertension. The Paradise Renal Denervation System will be used in this renal denervation procedure to treat hypertension that can not be controlled by medication. It works by by disabling the arterial nerves and lowering blood pressure.
  • This trial is looking to enroll patients with heart failure in order to study the effect and safety of the study drug, vericiguat, when compared to a placebo. Patients will remain on their regular standard of care treatment and will receive either a placebo or Vericiguat. All patients will be monitored closely by the study team.
  • This is designed for patients with severe, symptomatic mitral regurgitation who are not candidates for conventional mitral repair.
  • Study for subjects with moderate-to-severe or severe functional mitral regurgitation (MR) and you have been determined to have symptoms due to heart failure despite being treated with currently available therapies, and are not an appropriate candidate for mitral valve surgery.
  • This study is for patients who suffer from a condition where one of the blood vessels that deliver blood to your leg has a significant narrowing. This is called peripheral artery disease (PAD). The narrowing may be suitable for a treatment technique called balloon angioplasty. One of the therapies that has been used to treat PAD is balloon angioplasty. It is a procedure where a small balloon is inserted into the blood vessel next to the area that is narrowed and inflated temporarily.
  • A drug study looking at the effects of 10 mg Dapagliflozin vs. Placebo in patients with Heart Failure andPreserved Ejection Fraction (HFpEF) with either diabetes or per-diatbetes.
  • The purpose of this study is to evaluate a new device to treat patients who may benefit from the repair of their mitral heart valve due to mitral regurgitation. The device is called the Edwards Cardioband System (Edwards Cardioband System or the device). The device is investigational in the United States but has been approved in Europe. This clinical study is expected to take approximately 5 years to complete if you are eligible. You will need to return to your doctors office at 1 month, 6 months, and 1, 2, 3, 4 and 5 years after the device implant procedure.
  • The study is to determine whether aortic valve replacement is helpful for patients who have severe, calcific, aortic stenosis (a narrowing of the aortic heart valve, where calcium has attached to the valve surface, resulting in obstructed blood flow) and do not have symptoms.
  • We are doing this research study to learn more about human blood cells called monocytes. Currently, there are several well-documented types of monocytes, each having unique roles in our immune system and in heart and vascular diseases. This study will examine the genetic make-up of monocytes to identify new and unique subsets across different cardiovascular (CV) risk states, including Type II Diabetes (DM2), tobacco smoking, and high cholesterol. We are seeking to understand if some types of monocytes are more prevalent within specific cardiovascular risk states than others.
  • We are doing this research study to learn more about human blood cells called monocytes. Currently, there are several well-documented types of monocytes, each having unique roles in our immune system and in heart and vascular diseases. This study will examine the genetic make-up of monocytes to identify new and unique subsets across different cardiovascular (CV) risk states, including Type II Diabetes (DM2), tobacco smoking, and high cholesterol. We are seeking to understand if some types of monocytes are more prevalent within specific cardiovascular risk states than others.
  • We are doing this research study to learn more about human blood cells called monocytes. Currently, there are several well-documented types of monocytes, each having unique roles in our immune system and in heart and vascular diseases. This study will examine the genetic make-up of monocytes to identify new and unique subsets across different cardiovascular (CV) risk states, including Type II Diabetes (DM2), tobacco smoking, and high cholesterol. We are seeking to understand if some types of monocytes are more prevalent within specific cardiovascular risk states than others.
  • We are doing this research study to learn more about human blood cells called monocytes. Currently,there are several well-documented types of monocytes, each having unique roles in our immune system and in heart and vascular diseases. This study will examine the genetic make-up of monocytes to identify new and unique subsets across different cardiovascular (CV) risk states, including Type II Diabetes (DM2), tobacco smoking, and high cholesterol. We are seeking to understand if some types of monocytes are more prevalent within specific cardiovascular risk states than others.
  • Many patients want to know which blood pressure medication is the best for them. In this study, we will test the feasibility of a new approach to determining the best blood pressure (BP) medication for individual patients by performing an N-of-1 trial in which patients will have the opportunity to test a series of 3 blood pressure medications at escalating doses while carefully measuring their blood pressure and side-effects.
  • This clinical trial is for patients diagnosed with carotid artery stenosis that are at high risk of a stroke. Carotid artery stenosis develops as a result of plaque buildup in the carotid artery. Over time plaque buildup creates a narrowing of the carotid artery, restricting the flow of blood. Thus, increasing the risk of stroke. In this research study the Roadsaver and the Nanoparasol systems will be used to treat carotid artery stenosis.
  • This research study is for patients with severe aortic stenosis. Patients may be considered for this study if they have a diseased aortic heart valve and who are at low operative risk for standard (traditional) open-heart surgery for aortic valve replacement (TAVR).
  • The phrase sitting is the new smoking has been coined due to an increase of excessive sitting in middle- and older-aged adults. However, there are currently no specific guidelines for the best way to break up long periods of sitting. This study will look at the effect of breaking up sitting periods with movement breaks on blood sugar levels. We are looking for non-smoking, otherwise healthy adults,who sit for most of their day with little to no exercise. Participants will be asked to sit taking 1 or 5-minute walking breaks every 30 or 60 minutes over an 8-hour period.
  • This is a multicenter, prospective randomized study to determine the safety and efficacy of the Watchman device in patients with irregular heart beat undergoing a less invasive procedure than open heart surgery called Transcatheter Aortic Valve Replacement (TAVR). In this procedure, an x-ray is used to visualize and guide the Watchman device via a catheter to replace the heart valve. This is done for patients with aortic stenosis (AS) where there is reduced blood flow, pain and fatigue because the blood has to work harder to pump blood due to narrowed valves in the blood vessels.
  • This is a research study designed to look at the safety and effectiveness of the TriGUARD 3 cerebral embolic protection device in patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of the study is to assess whether the TriGUARD 3 can prevent death, stroke, more subtle signs of brain injury, and/or silent brain injury as measured by a magnetic resonance imaging (MRI) study of the brain.
  • This is a research study to evaluate the use of a device to treat patients with Heart Failure (HF) whohave moderate aortic stenosis (AS). The Edwards SAPIEN 3 has already been approved by the FDA for usein patients who require an aortic valve replacement due to severe aortic stenosis. This is an international,multicenter, randomized, openlabel, clinical trial comparing the safety and effectiveness of TAVR(Transcatheter Aortic Valve Replacement) with the Edwards SAPIEN 3 THV (transcatheter heart valve) andmedical therapy to medical therapy alone in HF patients with moderate AS.